Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > France rejects Trump's comment on drug prices, calls it 'fake news'
    Finance

    France rejects Trump's comment on drug prices, calls it 'fake news'

    Published by Global Banking & Finance Review®

    Posted on January 21, 2026

    3 min read

    Last updated: January 21, 2026

    France rejects Trump's comment on drug prices, calls it 'fake news' - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:Presidentfinancial communitycorporate governancefinancial servicesinternational organizations

    Quick Summary

    France denies Trump's assertion of drug price hikes due to tariff threats, labeling it 'fake news'. Macron's stance on drug pricing remains unchanged.

    Table of Contents

    • France's Response to Trump's Drug Price Comments
    • Background of the Dispute
    • Details of Trump's Claims
    • France's Official Stance

    France rejects Trump's comment on drug prices, calls it 'fake news'

    France's Response to Trump's Drug Price Comments

    By Louise Rasmussen

    Background of the Dispute

    PARIS, Jan 21 (Reuters) - France rejected as "fake news" on Wednesday Donald Trump's assertion that he had pressured President Emmanuel Macron into hiking domestic drug prices after the U.S. leader threatened sweeping tariffs on French imports to the United States.

    Details of Trump's Claims

    It was the latest salvo in an escalating war of words between the two NATO allies as Trump's threat to take control of Greenland and to impose tariffs on any country that stands in his way puts transatlantic relations under unprecedented strain.

    France's Official Stance

    "It is being claimed that President @Emmanuel Macron increased the price of medicines," the French presidency wrote on social media platform X.

    "He does not set their prices. They are regulated by the social security system and have, in fact, remained stable. Anyone who has set foot in a French pharmacy knows this."

    The Elysee used a GIF of Trump mouthing the words "fake news" in front of a microphone, with the same words in writing underneath.

    Earlier on Wednesday, Trump said in a speech at the World Economic Forum in Davos, Switzerland, that he had threatened Macron with tariffs to cajole him into increasing drug prices in France.

    'HERE'S THE STORY, EMMANUEL...'

    "I said, 'Here's the story, Emmanuel, the answer is, you're going to do it, you're going to do it fast. And if you don't, I'm putting a 25% tariff on everything that you sell into the United States, and a 100% tariff on your wines and champagnes," Trump said.

    "(And Macron said) 'No, no, Donald, I will do it, I will do it'. It took me on average three minutes a country, saying the same thing, 'You will do it'," Trump said.

    Trump earlier mocked Macron for the aviator sunglasses he wore during his own speech at Davos on Tuesday. Trump has also threatened to hit French wines and champagnes with 200% tariffs in an apparent effort to persuade him to join the U.S. leader's Board of Peace initiative aimed at resolving global conflicts.

    Macron has taken a harder line than most European Union leaders over Trump's Greenland threat, urging the bloc to activate its most potent trade tools against Washington and saying Europe would not give in to bullies.

    The French government last year set up an account called @frenchresponse to expose false narratives and misinformation. The account has become increasingly active in recent weeks, notably in challenging rhetoric from the Trump administration.

    (Reporting by David Ljunggren, John Irish and Louise RasmussenEditing by Ingrid Melander and Gareth Jones)

    Key Takeaways

    • •France rejects Trump's claim of drug price hikes.
    • •Macron does not control drug pricing in France.
    • •Trump threatened tariffs to pressure Macron.
    • •France uses social media to counter misinformation.
    • •Transatlantic relations are under strain.

    Frequently Asked Questions about France rejects Trump's comment on drug prices, calls it 'fake news'

    1What is fake news?

    Fake news refers to misinformation or false information presented as news. It is often spread through social media and can mislead the public on various issues.

    2What is a NATO ally?

    A NATO ally is a member country of the North Atlantic Treaty Organization, a military alliance formed for mutual defense and security among its members.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostVolkswagen reports stronger cash flow despite Porsche woes and weak China sales
    Next Finance PostSocGen to cut 1,800 jobs in France by end of 2027, union says